A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma Full Text
Journal of Gastrointestinal Oncology, 04/09/2012
Clinical Article
Frank D et al. – Although capecitabine and lapatinib is well tolerated, it is not an effective regimen in patients with refractory colorectal adenocarcinoma.



